Governance Indivior PLC London S.E.

INDV

GB00BN4HT335

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:04 2025-07-24 EDT			5-day change	1st Jan Change
1,238.00 ^GBX	+1.56%		-.--%	+20.90%

11-14	Camurus Competitor Exits Sweden - Di	FW
11-03	Indivior Presents New Real-World Evidence At AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	CI

Executive Committee: Indivior PLC

Manager

Positions heldSince

Joseph Ciaffoni

54 year

Chief Executive Officer

Christian Heidbreder

62 year

Chief Tech/Sci/R&D Officer

2014-11-30

Alice Givens

52 year

Corporate Secretary

Jason Thompson

Investor Relations Contact

2017-02-28

Vishal Kalia

44 year

Chief Operating Officer

2024-10-31

Jeffrey Burris

53 year

General Counsel

2021-11-30

Ryan Preblick

49 year

Director of Finance/CFO

2020-06-28

Kevin L. Espinoza

Compliance Officer

2025-09-30

Composition of the Board of Directors: Indivior PLC

Director

CommitteesSince

David Wheadon

68 year

Governance Committee	2021-04-30
Nominating Committee	2021-04-30
Compensation Committee Chair
Audit Committee	2021-04-30
Compensation Committee	2025-01-27
Nominating Committee Chair	2025-01-27

Barbara Ryan

65 year

Compensation Committee	2021-08-31
Audit Committee Chair	2021-08-31
Audit Committee	2020-08-31
Nominating Committee	2020-08-31
Compensation Committee Chair	2024-04-30
Governance Committee	2020-08-31

Juliet Thompson

58 year

Compensation Committee	2020-12-31
Nominating Committee	2020-12-31
Audit Committee Chair	2025-06-29
Governance Committee	2021-03-23

Daniel Ninivaggi

60 year

Finance Committee
Governance Committee
Nominating Committee
Nominating Committee Chair	2025-03-09

Mark Stejbach

62 year

Audit Committee	2021-03-23
Nominating Committee	2023-10-01

Tony Kingsley

61 year

Audit Committee	2025-06-30
Compensation Committee	2025-06-30

Keith Humphreys

58 year

Nominating Committee

2023-11-08

Joseph Ciaffoni

54 year

Director/Board Member

2024-12-16

Latest Appointments: Indivior PLC

07-08	Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs, Effective July 7, 2025	CI
06-24	Indivior PLC Appoints Tony Kingsley as Independent Non-Executive Director, Effective July 1, 2025	CI
06-02	PRESS DIGEST-British Business - June 3	RE
05-27	Indivior PLC Announces Patrick Barry as Chief Commercial Officer, Effective June 2, 2025	CI
03-04	Indivior Announces Further Changes To Board Of Directors	RE
03-04	Indivior shrinks size of board after US primary listing	AN
03-04	Indivior to Cut Board Size at May Shareholders' Meeting	MT

More news

Former Officers and Directors: Indivior PLC

Insider

Positions held

SinceUntil

Joanna Le Couilliard

Director/Board Member	2021-03-23	2025-05-07
Independent Dir/Board Member	2021-03-23	2025-05-07

Mark Crossley

Director/Board Member	2017-02-20	2025-05-07
Chief Executive Officer	2020-06-28	2025-05-07
Chief Operating Officer	2019-07-28	2020-06-28
Director of Finance/CFO	2017-02-20	2020-06-28
Corporate Officer/Principal	2014-09-30	2017-02-02

Peter Bains

Director/Board Member	2019-07-31	2025-05-07
Independent Dir/Board Member	2019-07-31	2025-05-07

Robert Schriesheim

Director/Board Member	2024-12-16	2025-03-01
Independent Dir/Board Member	2024-12-16	2025-03-01

Jerome Lande

Director/Board Member

2021-03-23

2024-12-30

Graham Hetherington

Director/Board Member	2019-10-31	2020-11-18
Chairman	2020-11-18	2024-12-30
Independent Dir/Board Member	2019-10-31	2020-11-18

A. McLellan

Director/Board Member	2014-11-03	2024-02-28
Independent Dir/Board Member	2014-11-03	2024-02-28

Daniel Phelan

Director/Board Member	2014-11-03	2023-09-29
Independent Dir/Board Member	2014-11-03	2023-09-29

Lorna Parker

Director/Board Member	2014-11-03	2023-09-29
Independent Dir/Board Member	2014-11-03	2023-09-29

Nina DeLorenzo

Corporate Officer/Principal

2022-06-15

Susan Learned

Corporate Officer/Principal

2015-07-31

2021-06-30

Daniel Tassé

Director/Board Member	2020-11-18	2021-05-05
Chairman	2020-06-14	2020-11-18
Independent Dir/Board Member	2020-11-18	2021-05-05

Javier Rodriguez

General Counsel

2014-11-30

2020-11-30

Rosh Dias

Chief Tech/Sci/R&D Officer

2019-10-31

2020-07-31

Tatjana Anni Hilde May

Director/Board Member	2017-01-31	2020-07-30
Independent Dir/Board Member	2017-01-31	2020-07-30

Shaun Thaxter

Director/Board Member	2014-11-03	2020-06-28
Chief Executive Officer	2014-11-03	2020-06-28

Howard H. Pien

Chairman

2014-11-03

2020-06-14

Frank Stier

Corporate Officer/Principal

2014-09-30

2020-01-31

Lizabeth Zlatkus

Director/Board Member	2016-08-31	2019-08-30
Independent Dir/Board Member	2016-08-31	2019-08-30

Christian Schade

Director/Board Member	2014-11-03	2019-07-30
Independent Dir/Board Member	2014-11-03	2019-07-30

Michael R. Clarke

Compliance Officer

2019-03-31

Ponni Subbiah

Chief Tech/Sci/R&D Officer

2016-09-30

2019-03-31

Yvonne Greenstreet

Director/Board Member	2014-11-03	2019-03-30
Independent Dir/Board Member	2014-11-03	2019-03-30

Cynthia Cetani

Compliance Officer

2018-09-30

Ingo Elfering

Chief Tech/Sci/R&D Officer

2014-10-31

2018-08-31

Cary Claiborne

Director/Board Member	2014-10-31	2017-01-31
Director of Finance/CFO	2014-10-31	2017-01-31

Tony Goodman

Corporate Officer/Principal

2014-09-30

2017-01-31

Rupert Bondy

Director/Board Member	2014-11-03	2016-09-29
Independent Dir/Board Member	2014-11-03	2016-09-29

Adrian Hennah

Director/Board Member

2014-11-03

2016-05-10

Timothy Baxter

Chief Tech/Sci/R&D Officer

2014-09-30

2016-04-30

Kathryn Hudson

Corporate Secretary

2015-07-14

Jon Fogle

Human Resources Officer

2014-09-30

Tom Corran

Investor Relations Contact

Debby Betz

Public Communications Contact

2014-09-30

Lola Emetulu

Corporate Secretary

Alex Lugovoy

Corporate Officer/Principal

Andraea Dawson-Shepherd

Public Communications Contact

Richard F. Joyce

Investor Relations Contact

Murali Gopal

Chief Tech/Sci/R&D Officer

Age distribution of managers

Parity Men Women

Male	16
Female	5

Of which Executive Committee

Male	7
Female	1

Of which Directors

Male	6
Female	2

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.

Employees

1,041

Sector

Pharmaceuticals

Calendar

02-11 - Q4 2025 Earnings Release (Projected)

More about the company